Key Products and Pipeline (FY2016 Q4 Pipeline Table)

●Phase 3 / Filed(4)
・Oncology(0)
・GI(1)
　CX601(TiGenix, mesenchymal stem cells, Perianal Fistulas in CD)
・CNS(1)
　AD-4833 TOMM40(Zinfandel Pharmaceutical, Mitochondrial growth modulator, Delay of MCI)
・Vaccines(1)
　TAK-003(Dengue Vaccine)
・Other(1)
　Relugolix(Myovant, GNRH antagonist, Uterine Fibroids(JP), Endometriosis, Prostate Cancer)

●Phase 2(5)
・Oncology(2)
　pevonedistat(NAE inhibitor, HR MDS)
　sapanisertib(TAK-228)(mTORC 1/2 inhibitor, RCC, Breast, Endometrial)
・GI(0)
・CNS(0)
・Vaccines(1)
　TAK-214(Norovirus Vaccine)
・Other(2)
　namilumab(Amgen, GM-CSF, RA)
　TAK-272(SCOHIA Pharma, Direct renin inhibitor, Diabetic Nephropathy)

●Phase 1(18)
・Oncology(7)
　TAK-202, TAK-243, TAK-659, TAK-580, TAK-931, TAK-778(AP32788), XMT-1522
・GI(2)
　TAK-954, TAK-906
・CNS(6)
　TAK-041, TAK-058, TAK-071, TAK-653, TAK-831, TAK-935
・Vaccines(1)
　TAK-021
・Other(2)
　TAK-079, TAK-020

●LCM(10)
・Oncology(5)
　NINLARO, ADCETRIS, ALUNBRIG(Brigatinib), ICLUSIG, Cabozantinib
・GI(3)
　ENTIVIO, TAKECAB, AMITIZA
・CNS(2)
　TRINTELLIX, Rasagiline
・Vaccines(0)
・Other(0)

https://www.takeda.com/what-we-do/research-and-development/our-pipeline/